Dehghan B, Abolhasanzadeh N, Shademan B, Nourazarian A
Front Mol Biosci. 2024; 11:1382555.
PMID: 39629040
PMC: 11613041.
DOI: 10.3389/fmolb.2024.1382555.
Asiri Y, Moni S, Ramar M, Chidambaram K
Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598351
PMC: 11597627.
DOI: 10.3390/ph17111439.
Vaelli P, Fujita A, Jo S, Zhang H, Osorno T, Ma X
Mol Pharmacol. 2024; 106(6):298-308.
PMID: 39322410
PMC: 11585256.
DOI: 10.1124/molpharm.124.000944.
Hu X, Shinn P, Itkin Z, Ye L, Zhang Y, Shen M
ACS Pharmacol Transl Sci. 2024; 7(8):2391-2400.
PMID: 39144561
PMC: 11320728.
DOI: 10.1021/acsptsci.4c00256.
Samanta S, Biswas P, OBannon B, Powers D
Angew Chem Int Ed Engl. 2024; 63(31):e202406335.
PMID: 38699820
PMC: 11262962.
DOI: 10.1002/anie.202406335.
In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin-Ranatensin Hybrid Peptide.
Hochrainer N, Serafin P, DIngiullo S, Mollica A, Granica S, Brytan M
Int J Mol Sci. 2024; 25(7).
PMID: 38612817
PMC: 11012005.
DOI: 10.3390/ijms25074007.
Genomic and Reverse Translational Analysis Discloses a Role for Small GTPase RhoA Signaling in the Pathogenesis of Schizophrenia: Rho-Kinase as a Novel Drug Target.
Tanaka R, Yamada K
Int J Mol Sci. 2023; 24(21).
PMID: 37958606
PMC: 10648424.
DOI: 10.3390/ijms242115623.
Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain.
Bernatoniene J, Sciupokas A, Kopustinskiene D, Petrikonis K
Pharmaceutics. 2023; 15(7).
PMID: 37513986
PMC: 10384314.
DOI: 10.3390/pharmaceutics15071799.
Profiling Chemobiological Connection between Natural Product and Target Space Based on Systematic Analysis.
Wang D, Li X, Miao Y, Zhang Q
Int J Mol Sci. 2023; 24(14).
PMID: 37511025
PMC: 10378764.
DOI: 10.3390/ijms241411265.
Allosteric Regulation of G-Protein-Coupled Receptors: From Diversity of Molecular Mechanisms to Multiple Allosteric Sites and Their Ligands.
Shpakov A
Int J Mol Sci. 2023; 24(7).
PMID: 37047169
PMC: 10094638.
DOI: 10.3390/ijms24076187.
The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.
Gribkoff V, Kaczmarek L
Adv Neurobiol. 2023; 30:255-285.
PMID: 36928854
PMC: 10599454.
DOI: 10.1007/978-3-031-21054-9_11.
Peripheral Regional Anesthesia Using Local Anesthetics: Old Wine in New Bottles?.
Gasteiger L, Kirchmair L, Hoerner E, Stundner O, Hollmann M
J Clin Med. 2023; 12(4).
PMID: 36836081
PMC: 9962037.
DOI: 10.3390/jcm12041541.
Use-Dependent Relief of Inhibition of Nav1.8 Channels by A-887826.
Jo S, Zhang H, Bean B
Mol Pharmacol. 2023; 103(4):221-229.
PMID: 36635052
PMC: 10029820.
DOI: 10.1124/molpharm.122.000593.
Cyclovirobuxine D, a cardiovascular drug from traditional Chinese medicine, alleviates inflammatory and neuropathic pain mainly inhibition of voltage-gated Ca3.2 channels.
Su D, Gong Y, Li S, Yang J, Nian Y
Front Pharmacol. 2023; 13:1081697.
PMID: 36618940
PMC: 9811679.
DOI: 10.3389/fphar.2022.1081697.
Synthesis and Characterization of an Analgesic Potential Conotoxin Lv32.1.
Liu S, Li C, You S, Yan Q, Luo S, Fu Y
Molecules. 2022; 27(23).
PMID: 36500709
PMC: 9741281.
DOI: 10.3390/molecules27238617.
Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CBR).
Ferrisi R, Gado F, Polini B, Ricardi C, Mohamed K, Stevenson L
Front Chem. 2022; 10:984069.
PMID: 36238097
PMC: 9551276.
DOI: 10.3389/fchem.2022.984069.
Interactive Effects of -Opioid and Adrenergic- Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine.
Obeng S, Leon F, Patel A, Zuarth Gonzalez J, Chaves Da Silva L, Restrepo L
J Pharmacol Exp Ther. 2022; 383(3):182-198.
PMID: 36153006
PMC: 9667981.
DOI: 10.1124/jpet.122.001192.
Inhibition of Na1.7: the possibility of ideal analgesics.
Kitano Y, Shinozuka T
RSC Med Chem. 2022; 13(8):895-920.
PMID: 36092147
PMC: 9384491.
DOI: 10.1039/d2md00081d.
Targeting Nuclear Receptors for Chronic Inflammatory Pain: A Potential Alternative.
Griffett K
ACS Pharmacol Transl Sci. 2022; 5(6):440-444.
PMID: 35711817
PMC: 9194933.
DOI: 10.1021/acsptsci.2c00063.
5-HT Receptor Modulators for Therapeutic Use in the Treatment of Obsessive-Compulsive Disorder and Other Psychological Disorders.
Kargbo R
ACS Med Chem Lett. 2022; 13(5):770-772.
PMID: 35586441
PMC: 9109471.
DOI: 10.1021/acsmedchemlett.2c00153.